LBRX News
Archived Headlines
- Renaissance Capital's August IPO Market Update 09/02/25
- LB Pharmaceuticals prepares to break the biotech IPO dry spell 08/26/25
- US IPO Weekly Recap: Public pipeline gives more clues about fall IPO activity as large names file 08/22/25
- Neuropsychiatry biotech LB Pharmaceuticals files for a $100 million IPO 08/22/25
US IPO Weekly Recap: Klarna leads busiest week for IPOs since 2021, as more names join the pipeline
7 sizable IPOs debuted this week, the most in nearly four years, joined by 3 SPACs. 10 IPOs and 6 SPACS submitting initial filings. Buy-now-pay-later e-commerce platform Klarna (KLAR) priced above its range to raise $1.4 billion at a market cap of...read more
LB Pharmaceuticals prices upsized IPO at $15 midpoint
LB Pharmaceuticals, a Phase 3-ready biotech developing therapies for neuropsychiatric diseases, raised $285 million in an upsized IPO by offering 19 million shares at $15, the midpoint of the $14 to $16 range. The New York, NY-based company originally filed to...read more
The IPO market gears up for the most active week since 2021 with 7 deals
The fall IPO season is in full swing with seven sizable deals on the calendar for this week, a nearly four year record in weekly activity. The seven issuers aim to raise a combined $3.9 billion, led by a billion-dollar offering from fintech unicorn Klarna. ...read more
Neuropsychiatry biotech LB Pharmaceuticals sets terms for $250 million IPO
LB Pharmaceuticals, a Phase 3-ready biotech developing therapies for neuropsychiatric diseases, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $250 million by offering 16.7 million shares at a price range of $14 to $16. At ...read more